Chimerix Seeks FDA Approval for New Drug Targeting Deadly Brain Cancer
Chimerix Seeks FDA Approval for New Drug Targeting Deadly Brain Cancer
Chimerix寻求FDA批准新药以治疗致命的脑癌
Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today confirms that the Company has submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) seeking accelerated approval for dordaviprone as a treatment for patients with recurrent H3 K27M-mutant diffuse glioma in the United States.
Chimerix（纳斯达克：CMRX）是一家生物制药公司，致力于开发能够显著改善和延长面临致命疾病的患者生命的药物。今天确认，公司已向美国食品和药物管理局（FDA）提交了一份新药申请（NDA），寻求对dordaviprone的加速批准，以治疗美国H3 K2700万突变弥漫性胶质瘤复发患者。
资讯热榜
更新时间